Article
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Anti-cancer drugs - 1 Jul 2012
Modest Dominik Paul, Reinacher-Schick Anke, Stintzing Sebastian, Giessen Clemens, Tannapfel Andrea, Laubender Ruediger Paul, Brodowicz Thomas, Knittelfelder Regina, Vrbanec Damir, Schmiegel Wolff, Heinemann Volker, Zielinski Christoph C
Abstract excerpt
KRAS p.G13D mutant metastatic colorectal cancer (mCRC) has been identified as representing a cetuximab-sensitive subtype of KRAS mutant mCRC. This analysis aims to answer the question of whether first-line treatment of p.G13D mCRCs should include cetuximab or bevacizumab. Fifty-four patients with p.G13D mutant mCRC were pooled in this analysis. All patients underwent systemic first-line treatment with a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.